Ustekinumab for ulcerative colitis: a nationwide real-life observational cohort study.

ABSTRACT:

Objective

This nationwide retrospective chart review study assessed ustekinumab treatment persistence and clinical outcomes of ustekinumab treatment in Finnish patients with ulcerative colitis in a real-world setting.

Methods

Data was collected retrospectively until April 2022 from patient charts for all patients with ulcerative colitis who started ustekinumab between September 2019 and December 2021 in 16 Finnish inflammatory bowel disease centers. The primary outcomes were persistence on ustekinumab and clinical remission/steroid-free clinical remission, defined as partial Mayo score <3 and a combined stool frequency and rectal bleeding subscore of ≤1 at 16 weeks and 1 year.

Results

The study included 221 patients with an average follow-up of 14.7 months and a media

SUBMITTER: Molander P 

PROVIDER: S-EPMC11867796 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature